Related Experiment Videos
[Porphyria cutanea tarda and hepatitis C virus]
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar, Bórgyógyászati Klinika.
Orvosi Hetilap
|January 10, 2002
Summary
Porphyria cutanea tarda (PCT) development involves genetics and environment. Screening PCT patients for hepatitis C virus (HCV) antibodies is crucial, especially for young men, due to its high prevalence.
Area of Science:
- Dermatology
- Hepatology
- Genetics
Context:
- Porphyria cutanea tarda (PCT) is influenced by genetic and environmental factors.
- Hepatitis C virus (HCV) infection is frequently observed in PCT patients.
- Previous studies indicate a higher prevalence of HCV in PCT populations globally.
Purpose:
- To investigate the prevalence of anti-HCV antibodies in PCT patients at the University of Debrecen.
- To analyze the correlation between HCV infection and clinical presentation in PCT patients.
- To highlight the importance of HCV screening in PCT management.
Summary:
- A study at the University of Debrecen found anti-HCV antibodies in approximately 55% of PCT patients diagnosed between 1990-1999.
- HCV prevalence in this cohort aligns with Southern-European rates.
- Risk factors identified include alcohol consumption in males and contraceptive use in females.
- Most patients had mild liver enzyme elevations, with few requiring liver biopsy for chronic hepatitis.
Impact:
- Emphasizes the critical need for routine anti-HCV antibody screening in all PCT patients.
- Highlights the potential quo ad vitam significance of identifying HCV in young male PCT patients.
- Informs clinical practice regarding the etiological investigation and management of PCT.